

## RESTRICTED BENEFITS

---

Selected Devices or Drug Products are eligible benefits with restrictions in the Alberta Drug Benefit List. For these products a comment is displayed in the List after the ingredient name. The comment initially states “RESTRICTED BENEFIT” and is followed by an explanation of the restriction. For an example, refer to the Legend in the Introduction section of the List.

### Products Designated as Restricted Benefits

---

The products listed below are restricted benefits in the List.

#### PTC 00:00:02

- **Diabetes Supplies** Blood Glucose Test Strips, Blood Letting Lancet, Insulin Pen Needles, Insulin Syringes, Urine Test Strips, Glucose Monitoring Transmitter, Glucose Monitoring Transmitter and Sensor

#### PTC 08:12.06.04

- **Cefadroxil** 500 mg oral capsule

#### PTC 08:12.07.08

- **Ertapenem** 1 g/vial injection
- **Meropenem** 500 mg/vial and 1 g/vial injection

#### PTC 08:12.07.12

- **Cefoxitin Sodium** 1 g/vial and 2 g/vial injection

#### PTC 08:12.12.92

- **Azithromycin** 600 mg oral tablet

#### PTC 08:12.16.08

- **Ampicillin** 250 mg and 500 mg oral capsule

#### PTC 08:12.16.16

- **Piperacillin Sodium/ Tazobactam Sodium** 2 g/vial / 250 mg/vial, 3 g/vial / 375 mg/vial, and 4 g/vial / 500 mg/vial injection

#### PTC 08:12.28.24

- **Linezolid** 600 mg oral tablet

#### PTC 08:14.08

- **Fluconazole** 10 mg/ml oral suspension
- **Isavuconazonium Sulfate** 100 mg capsule, 200 mg/vial injection
- **Itraconazole** 10 mg/ml oral suspension
- **Voriconazole** 50 mg and 200 mg oral tablet

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

**PTC 08:14.16**

- **Caspofungin** 50 mg/vial injection and 70 mg/vial injection

**PTC 08:16.92**

- **Rifabutin** 150 mg oral capsule

**PTC 08:18.08.20**

- **Lamivudine** 100 mg oral tablet
- **Tenofovir Disoproxil Fumarate** 300 mg oral tablet

**PTC 08:18.20**

- **Peginterferon Alfa-2A** 180 mcg/0.5 ml injection syringe

**PTC 08:18.32**

- **Adefovir Dipivoxil** 10 mg oral tablet
- **Entecavir** 0.5 mg oral tablet

**PTC 12:20.04**

- **Cyclobenzaprine HCL** 10 mg oral tablet

**PTC 12:92:00**

- **Varenicline Tartrate** 0.5 mg and 1 mg oral tablet, 0.5 mg/1 mg oral tablet
- **Varenicline Tartrate/ Varenicline Tartrate** 0.5 mg/1 mg oral tablet

**PTC 20:12.18**

- **Ticagrelor** 90 mg oral tablet

**PTC 28:08.08**

- **Codeine Phosphate/ Acetaminophen** 1.6 mg/ml / 32 mg/ml oral elixir

**PTC 28:16.08.04**

- **Aripiprazole** 2 mg and 5 mg oral tablet
- **Risperidone Tartrate** 1 mg/ml oral solution

**PTC 28:20.04**

- **Amphetamine Sulfate/ Amphetamine Aspartate/ Dextroamphetamine Sulfate/ Dextroamphetamine Saccharate** 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg oral extended-release capsule
- **Lisdexamfetamine Dimesylate** 20 mg, 30 mg, 40 mg, 50 mg, 60 mg oral capsule

**PTC 28:20.92**

- **Methylphenidate HCL** 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 70 mg, 80 mg, 85 mg, 100 mg oral controlled-release capsule

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

ALBERTA DRUG BENEFIT LIST

**PTC 28:32.28**

- **Almotriptan Malate** 6.25 mg and 12.5 mg oral tablet
- **Naratriptan HCL** 1 mg and 2.5 mg oral tablet
- **Rizatriptan Benzoate** 5 mg oral tablet, 10 mg oral tablet, 5 mg oral disintegrating tablet and 10 mg oral disintegrating tablet
- **Sumatriptan Hemisulfate** 5 mg/dose and 20 mg/dose nasal unit dose spray
- **Sumatriptan Succinate** 50 mg oral tablet, 100 mg oral tablet and 6 mg/syringe injection
- **Zolmitriptan** 2.5 mg oral tablet, 2.5 mg oral dispersible tablet and 5 mg/dose nasal unit dose spray

**PTC 48:10.24**

- **Montelukast Sodium** 4 mg oral chewable tablet, 4 mg oral granule, 5 mg oral chewable tablet, and 10 mg oral tablet

**PTC 52:92:00**

- **Aflibercept** 2 mg/vial injection
- **Brolucizumab** 6 mg/syringe injection
- **Ranibizumab** 2.3 mg/vial injection

**PTC 56:22.92**

- **Aprepitant** 80 mg oral capsule
- **Aprepitant/Aprepitant** 80 mg/125 mg oral capsule

**PTC 68:04:00**

- **Mometasone Furoate** 100 mcg/dose metered inhalation powder

**PTC 68:22:12**

- **Glucagon** 3 mg/dose nasal powder

**PTC 86:12:00**

- **Propiverine Hydrochloride** 5 mg oral tablet

**PTC 92:36:00**

- **Leflunomide** 10 mg and 20 mg oral tablet

**PTC 94:00:00**

- **Aerosol Holding Chamber** device
- **Aerosol Holding Chamber/Mask** infant, pediatric and adult chamber/mask device

## Limited Restricted Benefits

---

Selected Drug Products and Devices are eligible benefits with limits and restrictions in the Alberta Drug Benefit List. For these products a comment is displayed in the List after the ingredient name. The comment initially states “LIMITED RESTRICTED BENEFIT” and is followed by an explanation of the limits and restrictions. For an example, refer to the Legend in the Introduction of the List.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.